Cargando…

Immunogenicity of CAR-T Cell Therapeutics: Evidence, Mechanism and Mitigation

Chimeric antigen receptor T cell (CAR-T) therapy demonstrated remarkable success in long-term remission of cancers and other autoimmune diseases. Currently, six products (Kymriah, Yescarta, Tecartus, Breyanzi, Abecma, and Carvykti) are approved by the US-FDA for treatment of a few hematological mali...

Descripción completa

Detalles Bibliográficos
Autores principales:	Khan, Aalia N., Chowdhury, Ambalika, Karulkar, Atharva, Jaiswal, Ankesh Kumar, Banik, Ankit, Asija, Sweety, Purwar, Rahul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9169153/ https://www.ncbi.nlm.nih.gov/pubmed/35677038 http://dx.doi.org/10.3389/fimmu.2022.886546

Ejemplares similares

Lymphocytes in Cellular Therapy: Functional Regulation of CAR T Cells
por: Dwivedi, Alka, et al.
Publicado: (2019)

Corrigendum: Lymphocytes in Cellular Therapy: Functional Regulation of CAR T Cells
por: Dwivedi, Alka, et al.
Publicado: (2019)

Oncolytic immunovirotherapy for high-grade gliomas: A novel and an evolving therapeutic option
por: Asija, Sweety, et al.
Publicado: (2023)

Hydrogel scaffold with substrate elasticity mimicking physiological-niche promotes proliferation of functional keratinocytes
por: Mogha, Pankaj, et al.
Publicado: (2019)

CAR-T Cell Therapy: Mechanism, Management, and Mitigation of Inflammatory Toxicities
por: Fischer, Joseph W., et al.
Publicado: (2021)

T-Cell Dependent Immunogenicity of Protein Therapeutics Pre-clinical Assessment and Mitigation–Updated Consensus and Review 2020
por: Jawa, Vibha, et al.
Publicado: (2020)

Immunogenicity of Immunotoxins Containing Pseudomonas Exotoxin A: Causes, Consequences, and Mitigation
por: Mazor, Ronit, et al.
Publicado: (2020)

Combining deep mutational scanning to heatmap of HLA class II binding of immunogenic sequences to preserve functionality and mitigate predicted immunogenicity
por: Sivelle, Coline, et al.
Publicado: (2023)

Editorial: Immunogenicity of Proteins Used as Therapeutics
por: Sauna, Zuben E., et al.
Publicado: (2020)

Expanding the Therapeutic Window for CAR T Cell Therapy in Solid Tumors: The Knowns and Unknowns of CAR T Cell Biology
por: Watanabe, Keisuke, et al.
Publicado: (2018)

Next generations of CAR-T cells - new therapeutic opportunities in hematology?
por: Tomasik, Jaromir, et al.
Publicado: (2022)

Therapeutic Implications of Immunogenic Cell Death in Human Cancer
por: Palombo, Fabio, et al.
Publicado: (2014)

Immunogenicity of Protein Therapeutics: A Lymph Node Perspective
por: Fu, Kristy, et al.
Publicado: (2020)

Immune Tolerance-Adjusted Personalized Immunogenicity Prediction for Pompe Disease
por: De Groot, Anne S., et al.
Publicado: (2021)

Crosstalk between autophagy and metabolic regulation of (CAR) T cells: therapeutic implications
por: Panahi Meymandi, Ahmad Reza, et al.
Publicado: (2023)

Oxidized Hemoglobin Is Antigenic and Immunogenic in Lupus
por: Jain, Sonia, et al.
Publicado: (2017)

Engineering Cytoplasmic Signaling of CD28ζ CARs for Improved Therapeutic Functions
por: Meng, Xianhui, et al.
Publicado: (2020)

Efficient DNA Repair Mitigates Replication Stress Resulting in Less Immunogenic Cytosolic DNA in Radioresistant Breast Cancer Stem Cells
por: Meyer, Felix, et al.
Publicado: (2022)

Immunogenicity of Bioproducts: Cellular Models to Evaluate the Impact of Therapeutic Antibody Aggregates
por: Nabhan, Myriam, et al.
Publicado: (2020)

Identification of Potentially Therapeutic Immunogenic Peptides From Paracoccidioides lutzii Species
por: Silva, Leandro B. R., et al.
Publicado: (2021)

Immunogenicity Risk Assessment of Spontaneously Occurring Therapeutic Monoclonal Antibody Aggregates
por: Swanson, Michael D., et al.
Publicado: (2022)

The immunogenicity of human-origin therapeutic antibodies are associated with V gene usage
por: Hu, Zicheng, et al.
Publicado: (2023)

PD-1(Hi) CAR-T cells provide superior protection against solid tumors
por: Sailer, Cooper J., et al.
Publicado: (2023)

Aggregation of protein therapeutics enhances their immunogenicity: causes and mitigation strategies
por: Lundahl, Mimmi L. E., et al.
Publicado: (2021)

CAR Talk: How Cancer-Specific CAR T Cells Can Instruct How to Build CAR T Cells to Cure HIV
por: Kim, Gloria B., et al.
Publicado: (2019)

Advancements in CAR-NK therapy: lessons to be learned from CAR-T therapy
por: Kilgour, Marisa K., et al.
Publicado: (2023)

Allogeneic CAR T Cells: An Alternative to Overcome Challenges of CAR T Cell Therapy in Glioblastoma
por: Martínez Bedoya, Darel, et al.
Publicado: (2021)

CAR T-Cell Therapy: Is CD28-CAR Heterodimerization Its Achilles’ Heel?
por: Ferreira, Leonardo M. R., et al.
Publicado: (2021)

CAR T cell therapy becomes CHIC: “cytokine help intensified CAR” T cells
por: Thomas, Simone, et al.
Publicado: (2023)

Altering the Immunogenicity of Hemagglutinin Immunogens by Hyperglycosylation and Disulfide Stabilization
por: Thornlow, Dana N., et al.
Publicado: (2021)

Immunogenic Cell Death and Role of Nanomaterials Serving as Therapeutic Vaccine for Personalized Cancer Immunotherapy
por: Catanzaro, Elena, et al.
Publicado: (2022)

Gamma-Delta CAR-T Cells Show CAR-Directed and Independent Activity Against Leukemia
por: Rozenbaum, Meir, et al.
Publicado: (2020)

Ciltacabtagene autoleucel: The second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma
por: Chekol Abebe, Endeshaw, et al.
Publicado: (2022)

Immunogenicity of Anti-TNF-α Biotherapies: I. Individualized Medicine Based on Immunopharmacological Evidence
por: Bendtzen, Klaus
Publicado: (2015)

Immunogenicity of Influenza Vaccines: Evidence for Differential Effect of Secondary Vaccination on Humoral and Cellular Immunity
por: Rosendahl Huber, Sietske K., et al.
Publicado: (2019)

CAR T Cell Therapy for Neuroblastoma
por: Richards, Rebecca M., et al.
Publicado: (2018)

TME-targeted approaches of brain metastases and its clinical therapeutic evidence
por: Khan, Ibrar Muhammad, et al.
Publicado: (2023)

Use of Cell and Genome Modification Technologies to Generate Improved “Off-the-Shelf” CAR T and CAR NK Cells
por: Morgan, Michael A., et al.
Publicado: (2020)

Custom CARs: Leveraging the Adaptability of Allogeneic CAR Therapies to Address Current Challenges in Relapsed/Refractory DLBCL
por: Jeyakumar, Nikeshan, et al.
Publicado: (2022)

Immunogenicity of TNF-Inhibitors
por: Atiqi, Sadaf, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_aas5s5fbs8hg8o6dcdn9l0b0mo